TY - JOUR
T1 - Low-value approvals and high prices might incentivize ineffective drug development
AU - Prasad, Vinay
AU - McCabe, Christopher
AU - Mailankody, Sham
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Drug regulators' acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.
AB - Drug regulators' acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.
UR - http://www.scopus.com/inward/record.url?scp=85047011186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047011186&partnerID=8YFLogxK
U2 - 10.1038/s41571-018-0030-2
DO - 10.1038/s41571-018-0030-2
M3 - Article
C2 - 29760505
AN - SCOPUS:85047011186
VL - 15
SP - 399
EP - 400
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
SN - 1759-4774
IS - 7
ER -